Payment overview · 2025
General Payments
$212.99
2 reported records · 2 companies
Healthcare provider profile · identity verified
Virind D Gupta, M.D.
Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine · SARASOTA, FL · NPI 1154436889
Verified facts
What the public records show
CMS Open Payments records show Virind D Gupta, M.D. received $212.99 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $121.02 | 56.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $91.97 | 43.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $212.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.02 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $91.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1133 | 87 |
| Morphine Sulfate Er | Morphine Sulfate | 1114 | 86 |
| Gabapentin | Gabapentin | 759 | 69 |
| Ibuprofen | Ibuprofen | 582 | 57 |
| Alprazolam | Alprazolam | 510 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 363 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 334 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 210 | 22 |
| Lisinopril | Lisinopril | 202 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 35 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 190 | 15 |
| Clonidine Hcl | Clonidine Hcl | 179 | 24 |
| Trazodone Hcl | Trazodone Hcl | 174 | 13 |
| Metformin Hcl | Metformin Hcl | 157 | 33 |
| Diazepam | Diazepam | 151 | 14 |
| Omeprazole | Omeprazole | 150 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 14 |
| Morphine Sulfate | Morphine Sulfate | 129 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 25 |
| Sertraline Hcl | Sertraline Hcl | 125 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 115 | 15 |
| Hydromorphone Hcl | Hydromorphone Hcl | 114 | suppressed |
| Pregabalin | Pregabalin | 107 | suppressed |
| Chlorthalidone | Chlorthalidone | 100 | 25 |
| Olanzapine | Olanzapine | 91 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | suppressed |
| Oxycontin | Oxycodone Hcl | 90 | suppressed |
| Xtampza Er | Oxycodone Myristate | 90 | suppressed |
| Aripiprazole | Aripiprazole | 84 | suppressed |
| Methadone Hcl | Methadone Hcl | 83 | 11 |
| Progesterone | Progesterone, Micronized | 83 | suppressed |
| Clonazepam | Clonazepam | 82 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | suppressed |
| Temazepam | Temazepam | 78 | suppressed |
| Ondansetron Odt | Ondansetron | 76 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 74 | suppressed |
| Meloxicam | Meloxicam | 74 | 11 |
| Fentanyl | Fentanyl | 71 | 11 |
| Lidocaine | Lidocaine | 71 | suppressed |
| Lorazepam | Lorazepam | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | suppressed |
| Losartan Potassium | Losartan Potassium | 64 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 63 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 12 |
| Linzess | Linaclotide | 61 | suppressed |
| Baclofen | Baclofen | 60 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 56 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | suppressed |
| Nifedipine Er | Nifedipine | 54 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | suppressed |
| Celecoxib | Celecoxib | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 49 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | suppressed |
| Topiramate | Topiramate | 47 | suppressed |
| Sucralfate | Sucralfate | 46 | suppressed |
| Prednisone | Prednisone | 44 | 30 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 17 |
| Furosemide | Furosemide | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Naproxen | Naproxen | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 12 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 17 |
| Carvedilol | Carvedilol | 25 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Dotti | Estradiol | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 11 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 16 |
| Ozempic | Semaglutide | 18 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxymorphone Hcl | Oxymorphone Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $212.99 · 2 records | ABBVIE INC. | General - Pain Management, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error